Amgen Ends Kyowa Kirin Collaboration in Strategic Shift

The latest announcement is out from Amgen ( (AMGN) ).

On January 30, 2026, Amgen Inc. and Kyowa Kirin Co., Ltd. agreed to terminate their June 1, 2021 License and Collaboration Agreement under a newly executed Termination Agreement, with the termination to take effect upon receipt of regulatory approval. The move effectively ends the companies’ prior licensing and co-development partnership, signaling a strategic shift in how Amgen will manage and pursue the assets or territories previously governed by the collaboration, with potential implications for its pipeline structure and partnering strategy once the termination becomes fully effective.

The most recent analyst rating on (AMGN) stock is a Buy with a $400.00 price target. To see the full list of analyst forecasts on Amgen stock, see the AMGN Stock Forecast page.

Spark’s Take on AMGN Stock

According to Spark, TipRanks’ AI Analyst, AMGN is a Outperform.

Amgen’s overall stock score is driven by strong financial performance and positive earnings call insights. The stock shows bullish technical indicators, although the high P/E ratio suggests potential overvaluation. The company’s strategic initiatives and robust revenue growth are significant positives, but the high debt level and competitive pressures pose risks.

To see Spark’s full report on AMGN stock, click here.

More about Amgen

Amgen Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering innovative human therapeutics, with a portfolio concentrated in areas such as oncology, inflammation, cardiovascular disease and other serious illnesses, primarily serving patients worldwide through biologic and targeted therapies.

Average Trading Volume: 2,914,497

Technical Sentiment Signal: Buy

Current Market Cap: $184.3B

Find detailed analytics on AMGN stock on TipRanks’ Stock Analysis page.